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Introduction
Chronic kidney disease (CKD) has become a signifi cant 
global health problem. For example, prevalence rates of CKD 
in Australia and the United States are approximately 16% 
and 13% respectively, while the number of patients requiring 
dialysis in Australia has more than doubled in the past 
decade.1-3 Creatinine is a well established biochemical marker 
for renal function and it is now widely used to estimate the 
glomerular fi ltration rate (eGFR).4-6 The measurement of 
creatinine has also been the subject of considerable recent 
international attention to align all current methods (including 
point-of-care) to isotope dilution mass spectrometry (IDMS) 
equivalent standards.7 There are now a number of options for 
measuring creatinine by PoCT devices, which can be applied 
in different clinical settings including the hospital emergency 
department, risk assessment prior to the administration of 
contrast media, and community-based screening.8,9 
PoCT Devices for Creatinine
The range of PoCT devices for measuring creatinine that 
are marketed globally is summarised in Tables 1 and 2. In 
addition, a creatinine module for the GEM Premier 4000 
(Abacus ALS) device is known to be under development.10,11 
PoCT creatinine devices can be conveniently divided into two 
types: those that are primarily blood gas analysers that offer 
creatinine as one of the metabolites that they measure; and 
those that are ‘non blood gas’ analysers. The i-STAT and ABL 
devices are examples of the former category that are available 
in Australasia, while the Refl otron, Dri-Chem, StatSensor and 
Piccolo are Australasian examples of the latter category. 
Table 3 summarises the non-analytical specifi cations of 
those devices currently in Australasia. Method principles 
are based on a cascade of enzymatic reactions, followed by 
either photometric or electrochemical detection. In terms 
of calibration, the ABL is IDMS-aligned while others are 
traceable to IDMS through Standard Reference Material 
(SRM) products. Measurement consumables range from 
strips to cassettes and cartridges to a rotor system. Preferred 
sample types vary from whole blood to serum/plasma or 
both. Sample volumes range from 1 to 30 μL generally, but 
the i-STAT requires 65 μL of venous whole blood and the 
ABL systems even more, depending on sample type. All 
devices have rapid turnaround times for results varying from 
30 seconds to 5 minutes, except the Piccolo which takes 8.5 
minutes for the fi rst result and 40 seconds thereafter for each 
subsequent result. Measuring ranges are generally very wide. 
Some devices such as the ABL, Refl otron and StatSensor can 
provide an automatic calculation of eGFR, using aligned and 
non-aligned Modifi cation of Diet in Renal Disease (MDRD) 
formulae. The i-STAT and StatSensor are hand-held devices 
while the remainder are benchtop, weighing 5 kg or more. 
The ABL and Dri-Chem systems are heavier again (more than 
20 kg) and more suited to the hospital or satellite laboratory 
environment than the community-based screening setting for 
example. The i-STAT and NovaStat devices both work off 
battery as well as mains power. All have good connectivity 
to laboratory or clinical information systems. Apart from 
the StatSensor which is a discrete whole blood creatinine 
measuring device, all other instruments can test for a range 
of other analytes.
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Analytical Performance Standards
To the author’s knowledge, there are no analytical performance 
standards that relate specifi cally to PoCT creatinine methods 
and devices. However, as PoCT methods should strive to be 
of equivalent analytical standard to those of the laboratory, it 
is appropriate to apply currently accepted specifi cations for 
laboratory measurement of creatinine to PoCT.12 Analytical 
goals derived from biological variation allow for a minimum 
total error goal of 11.4% (comprising a goal for imprecision 
of 3.2% and a goal for bias of 5.1%), desirable total error 
of 7.6% (2.2% for imprecision and 3.4% for bias) and 
optimal total error of 3.8% (1.1% for imprecision and 1.7% 
for bias).7,13 Westgard has recently updated the desirable 
analytical goals for serum creatinine to 8.2% for total error, 
3.8% for imprecision and 2.7% for bias.14
The Laboratory Working Group of the National Kidney Disease 
Education Program (NKDEP) stated that the combination of 
systematic bias and random error should not give rise to an 
error in eGFR calculation of >10%.7 In real terms this goal 
is a trade-off between imprecision and bias, with the lower 
the method bias, the wider the allowable imprecision. The 
NKDEP further stated that, after recalibration to IDMS, 
imprecision should be <8% and bias with respect to IDMS 
should be <5% at a serum creatinine concentration of 88.4 
μmol/L (1.00 mg/dL).7 (The <8% imprecision goal includes 
inter-laboratory variation.)
For many years, the allowable limit of performance for blood 
creatinine in the RCPA Quality Assurance Program’s (QAP) 
General Chemistry Program in Australasia has been ±10 up 
to 100 μmol/L and 10% for concentrations ≥100 μmol/L.15 In 
August 2010, this limit was tightened to ±8 up to 100 μmol/L 
and 8% for concentrations ≥100 μmol/L.
State-of-the-Art Performance for PoCT Creatinine 
Devices
Large-scale Multi-device Evaluations
In 2010, the National Health Service (NHS) in the United 
Kingdom published an excellent evaluation report on seven 
PoCT creatinine devices (all the above mentioned devices 
except the two Nova analysers).16 In terms of accuracy, most 
Table 1. PoCT creatinine analysers available globally.
Type Device Manufacturer In Australia and New Zealand
Blood Gas i-STAT Abbott POC Yes
ABL 700/800 Radiometer Yes
IRMA TRUpoint ITC No
Stat Profi le CCX Nova Biomedical No
Non Blood Gas Stat Sensor Nova Biomedical Yes
Piccolo xpress Abaxis Yes
Refl otron Plus Roche Yes
Dri-Chem 4000 FujiFilm, Japan Yes*
Pentra C200 Horiba, France No
*Not confi rmed for New Zealand.
The GEM Premier 4000 (Abacus ALS) is likely to be available in Australasia in late 2011.
Table 2. PoCT creatinine devices not available in Australia and New Zealand.
Device IRMA TRU point Stat Profi le CCX Pentra C200
Manufacturer ITC Nova Biomedical Horiba
Method Principle Enzymatic with 
amperometric biosensor
Enzymatic with 
amperometric biosensor
Jaffe
Calibration Traceable To NIST NIST 914a NIST SRM 967
Measurement Consumable Cartridge Sensor and cap Cuvette
Sample Type Whole blood (A,V,C) Whole blood, serum or plasma Serum or plasma
Sample Volume 200 μL 120 μL 9 μL
Time for Result 2.6 min 2.5 min 8.5 min (fi rst result) 
NIST = National Institute of Standards and Technology, SRM = Standard Reference Material; A = arterial, V = venous, C = 
capillary.
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devices showed a positive bias of 10–15% relative to the 
IDMS method. For those devices which used whole blood as 
the preferred sample type, the Piccolo and i-STAT displayed 
best agreement (that is, the smallest bias for patient and/or 
spiked patient samples) with the IDMS method. For those 
using serum or plasma, the Piccolo and Dri-Chem devices 
showed closest agreement with patient and/or spiked patient 
samples. 
Using the 5-day CLSI EP15-A protocol17 to assess imprecision, 
none of the devices tested met the minimum goal derived from 
biological variation at the lowest creatinine concentration 
tested (70 μmol/L). The best imprecision at this concentration 
was observed with the Pentra (3.6%), followed by the 
i-STAT (4.1%). The i-STAT met the minimum and desirable 
biological variation goals at 150 and 550 μmol/L, the Piccolo 
met the desirable goal at 150 μmol/L and the optimal goal at 
550 μmol/L, while the Dri-Chem met the minimum goal at 
550 μmol/L only.
Imprecision was also assessed using patient duplicates 
(n=25). For whole blood, the best imprecision (paired SD <15 
μmol/L) was achieved by the ABL 800 and Piccolo devices. 
For serum/plasma, the best imprecision was observed with the 
Pentra C200. 
The NHS study also looked at the effect of the accuracy of 
each PoCT device (relative to the IDMS method) on eGFR 
results for a 60-year-old white male at six different creatinine 
concentrations. At IDMS creatinine concentrations of 30, 60 
and 300 μmol/L, differing accuracy bases between the PoCT 
devices did not change CKD staging. At IDMS creatinine 
concentrations of 90, 120 and 150 μmol/L there were some 
changes in CKD staging for some devices. Specifi cally 
looking at the devices available in Australia, the i-STAT, ABL 
(both sample types) and Piccolo (whole blood) recorded the 
same CKD staging as IDMS results at all concentrations, 
whereas the Dri-Chem and Refl otron Plus underestimated the 
stage of CKD at creatinine concentrations between 90 and150 
μmol/L. 
The i-STAT and the ABL were interference-free with the 
compounds tested (bilirubin, glucose, haemoglobin and 
lipids). The Refl otron showed very slight interference with 
bilirubin, the Piccolo showed interference with bilirubin 
and lipids, while very slight interference was observed with 
glucose on the Dri-Chem. The effects of other interferents are 
covered elsewhere in the literature.4,7,9
Performance Data from RCPA Quality Assurance Programs 
At the time of writing, the Nova StatSensor and Piccolo 
devices are not currently enrolled in any quality assurance 
program offered by the RCPA Chemical Pathology QAP. The 
i-STAT and ABL 700/800 devices are well-represented in the 
Blood Gases and Co-oximetry Program (with approximately 
50 and 30 participants respectively), while there is a small 
number (approximately 5) of Refl otron and Dri-Chem devices 
in the Near Patient Testing program. Over the past year, the 
median imprecision achieved by the i-STAT and ABL 700/800 
devices has averaged 3.9% and 3.3% respectively. The 
median imprecision recorded by laboratories in the General 
Chemistry Program over the same time period was 3.3%. 
As mentioned earlier, the minimum goal for imprecision 
from biological variation is 3.2%. Thus the i-STAT and 
ABL devices can achieve imprecision close to the current 
median laboratory performance and the analytical goal from 
biological variation. There was insuffi cient data available to 
comment on other devices.
Single-device Evaluations
There are some excellent papers in the recent literature 
which have evaluated PoCT devices for creatinine either 
individually or in small comparative studies.9,18-20 In the 
author’s Community Point-of-Care Services (CPS) unit at 
Flinders University, we have evaluated the i-STAT device in 
fi eld and laboratory studies and the Nova StatSensor device in 
laboratory studies.
The Abbott i-STAT is used in 35 remote health centres in the 
Northern Territory POCT Program, which is a partnership 
between our Flinders CPS unit and the Northern Territory 
Department of Health and Families. The i-STAT has also 
been used in the Kidney Evaluation for You (KEY) Study, 
a partnership between Kidney Health Australia and our CPS 
unit.8,21 The KEY study was a targeted community-based 
screening program for CKD risk that involved 402 patients 
from three community locations across urban, rural and 
remote Australia. As part of the study, the i-STAT was used 
to measure whole blood creatinine, from which the eGFR 
and CKD staging were calculated ‘on the spot’ and fed back 
to patients. Prior to fi eld use, the i-STAT underwent a full 
internal evaluation and IDMS alignment (against the Roche 
Creatinine Plus enzymatic laboratory method on the Hitachi 
Modular P unit). Post-alignment, the bias on the i-STAT was 
eliminated (average 0.2% across all concentrations). The 
imprecision (from duplicate patient samples) observed in the 
evaluation was 5.5% across all concentrations. In the KEY 
fi eld study, imprecision on the i-STAT (assessed by between-
day bi-level quality control testing, n=16) averaged 4.5%.21
The Nova StatSensor was evaluated with a view to using this 
device in large-scale screening situations, due to its ability to 
use a fi nger-prick sample and provide a result with calculated 
eGFR in just 30 seconds.22 However, in our hands, the device 
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exhibited poorer between-day imprecision than the i-STAT 
(7.8% at all concentrations), poor between-device agreement, 
and a signifi cant negative bias of 47 μmol/L across all 
concentrations. IDMS alignment failed to improve the ability 
of the device to accurately identify patients with an eGFR of 
<60 mL/min/1.73m2, with many falsely low eGFR results that 
required laboratory confi rmation. 
Summary and Limitations
Globally there are currently at least nine devices that are 
available to measure whole blood or serum/plasma creatinine 
by PoCT. In Australasia, the number of PoCT devices used 
widely in laboratory or community health settings is limited 
primarily to the i-STAT and ABL instruments. Many challenges 
remain for PoCT creatinine device manufacturers. Only one 
device has undergone full IDMS alignment, with the remainder 
still exhibiting varying degrees of positive bias. Most devices 
exhibit poor precision at low creatinine concentrations (<120 
μmol/L), concentrations which may (depending on age and 
sex) often correspond closely to an eGFR cut-off of 60 mL/
min/1.73m2 and Stage 3 CKD. Creatinine measurement in 
whole blood is challenging due to the complexity of its matrix 
(including variations in haematocrit) and infl uences arising 
from different disease states (e.g. hyperglycaemia, uraemia 
and treatment medications).9
With the prevalence of CKD increasing across the world, 
the need for good screening methods for identifying CKD 
risk is becoming more important. A PoCT device fi t-for-
purpose in this setting requires not only capillary sampling, 
fast turnaround of result and automatic eGFR calculation, but 
also good analytical performance specifi cations to correctly 
categorise CKD risk. Currently no device fulfi ls these 
requirements.
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